

17 **Abstract**

18 The most critical step in the clinical diagnosis workflow is the pathological evaluation of each
19 tumor sample. Deep learning is a powerful approach that is widely used to enhance diagnostic
20 accuracy and streamline the diagnosis process. In our previous study using omics data, we
21 identified two distinct subtypes of pure seminoma. Seminoma is the most common histological
22 type of testicular germ cell tumors (TGCTs). Here we developed a deep learning decision making
23 tool for the identification of seminoma subtypes using histopathological slides. We used all
24 available slides for pure seminoma samples from The Cancer Genome Atlas (TCGA). The
25 developed model showed an area under the ROC curve of 0.896. Our model not only confirms the
26 presence of two distinct subtypes within pure seminoma but also unveils the presence of
27 morphological differences between them that are imperceptible to the human eye.

28

29 **Keywords:** bioinformatics, computational biology, deep learning, seminoma, subtypes

30

31 **Introduction**

32 Testicular seminoma is the most prevalent histological subtype of testicular germ cell tumors
33 (TGCT), accounting for the highest incidence rate among all types of testicular cancer ¹. TGCTs
34 are the most frequent type of solid cancer affecting men between the ages of 15 and 44 ¹ and rank
35 second among adult cancers in terms of life years lost per person dying of cancer ². The treatment
36 protocol for seminoma typically includes orchiectomy followed by either platinum-based
37 chemotherapy utilizing cisplatin or radiation therapy ³. While current treatments for seminoma
38 have high efficacy and survival rates for patients, they also carry the risk of around 40 severe and
39 potentially life-threatening long-term side effects, such as infertility, neurotoxicity,
40 hypercholesterolaemia, secondary cancers and death ⁴. The presence of elevated platinum
41 concentrations from chemotherapy in the bloodstream can persist at levels up to 1,000 times higher
42 than the norm for a duration of 20 years, potentially contributing to various long-term effects ⁵.
43 Prolonged exposure to elevated platinum levels can result in vascular damage and is highly likely
44 to be linked with the onset of neuropathy ⁶ and cardiovascular diseases ⁷. After undergoing
45 chemotherapy, patients with TGCT exhibited a decrease of 3.6 dB in hearing for each additional
46 100 mg/m² of cumulative cisplatin dose ^{8,9}. Relapse occurs in approximately 20% of seminoma
47 cases, and the underlying reasons for this phenomenon remain unclear ¹⁰, however there are several
48 well-known seminoma risk factors such as rete testis, lymphovascular invasion, cryptorchidism,
49 mutations in KRAS and KIT genes ^{11,12}. Patients experiencing a relapse will receive further
50 treatment involving chemotherapy and radiation therapy, which intensify the side effects
51 considerably. Recently we discovered two distinct subtypes of pure seminoma of the testis based
52 on omics data ^{13,14}. Two identified seminoma subtypes revealed significant differences in the rates
53 of loss of heterozygosity, the level of expression of lncRNA associated with cisplatin resistance,

54 the activity of double stranded DNA breaks repair mechanisms and the pluripotency stage.
55 Seminoma subtype 1 exhibits a higher pluripotency state, while subtype 2 reveals attributes of
56 reprogramming into non-seminomatous lineages of TGCT, which are more aggressive and require
57 higher dose of chemotherapy drugs ³. We showed that subtype 1 of seminoma, which is less
58 differentiated, exhibits an immune microenvironment characterized by a significantly lower
59 immune score and a larger fraction of neutrophils ¹⁴. These features are indicative of the immune
60 microenvironment at an early developmental stage. Moreover, subtype 2 revealed the
61 overexpression of genes related to the senescence-associated secretory phenotype, which might be
62 one of the reasons for seminoma immunotherapy failure ¹⁴. Therefore, we suggested that seminoma
63 subtype 2 might require an adjustment to its treatment strategy. The development of subtype-
64 specific therapy for seminoma can reduce the risk of chemotherapy overtreatment in TGCT
65 patients and enhance the quality of life for TGCT survivors.

66 Deep learning (DL) is a powerful tool capable of extracting previously hidden information directly
67 from routine histopathology images of cancer tissue, simplifying, speeding up, and automating
68 clinical decision-making ¹⁵. The performance of modern DL methods applied to pathological data
69 often exceeds that of human pathologists ¹⁵. Most pathologists work under conditions of an
70 extreme work overload ¹⁶. An overworked pathologist can result in the misinterpretation of
71 pathological data that affects patients' health and quality of life. DL applications aim to simplify
72 and speed up routine pathological workflows and reduce pathologists' overload burden.

73 Here, we have developed a DL-based approach to examine potential histopathologic differences
74 between seminoma subtypes that were previously identified using omics data. Additionally, our
75 goal is to utilize this approach to detect and classify these subtypes based on histopathological
76 slides. Our findings demonstrate that pure seminoma subtypes cannot be classified solely based on

77 histopathological features. However, the developed DL-based model revealed histopathological
78 differences between these subtypes, as indicated by the area under the ROC curve (AUC) values.
79

80 **Materials and Methods**

81 **Data set preparation**

82 We used all hematoxylin and eosin (H&E) histopathological slides available at The Cancer
83 Genome Atlas (TCGA) data portal (TCGA-TGCT study) for 64 pure seminoma, which comprised
84 156 whole slide images (WSIs). Based on our previous study, we assigned 40 out of 64 samples
85 to seminoma subtype 1 (101 WSIs) and the remaining 24 samples to seminoma subtype 2 (55
86 WSIs)¹³. Pure seminoma regions of interest (ROIs) were designated and verified for each WSI by
87 a genitourinary specialized pathologist using Aperio ImageScope version 12.1. During our analysis
88 of pure seminoma H&E slides from the TCGA portal, we identified two samples (TCGA-2G-
89 AAG9, TCGA-2G-AAH0), initially reported as pure seminoma. However, upon further
90 examination, they should be reclassified as mixed GCT since they contain other types of GCT
91 (teratoma and embryonal carcinoma) in addition to seminoma (Fig.1). Consequently, these cases
92 were removed from our data set.

93 Verified ROIs were subsequently split into smaller tiles (300x300 pixels) at a 20X magnification
94 with a 50% overlap using DeepPath package¹⁷ (Fig. 2). Tiles that contained more than 20% of
95 background were removed. We conducted a manual check and excluded tiles of poor quality that
96 contained out of focus images and defects, such as scratches, dirt and folded tissue. TGCTs are
97 relatively uncommon compared to other cancers², and therefore histopathological data availability
98 is limited. Thus, image data augmentation technique was applied to the dataset of tiles to create
99 synthetic variations of the images and expand the training dataset. We used the following
100 augmentations from the Imgaug library¹⁸: random rotation by 0°, 90°, 180°, 270°, random increase
101 and decrease of contrast, brightness and saturation.

102

103 **Training the model**

104 We conducted all computational experiments at the BioHPC computing facility (Lyda Hill
105 Department of Bioinformatics, UT Southwestern Medical Center, TX, USA). TensorFlow package
106 ¹⁹ version 2.5.0 was used for developing DL model based on Convolution Neural Networks
107 (CNNs) method. The software stack for GPU acceleration included CUDA 11.2 and cuDNN 8.1.
108 We employed a convolutional neural network with MobileNet ²⁰ architecture that includes 85
109 convolutional layers. During the training top 29 convolutional layers were kept frozen (fixed). We
110 used sigmoid activation and the Binary Cross Entropy loss function, which is used when there are
111 only two label classes (seminoma subtypes 1 and 2). The Adam optimizer was selected due to its
112 superior performance in terms of both speed of convergence and accuracy ²¹ with a learning rate
113 of 0.001. Due to imbalanced dataset we used subtype (class) weights calculated as follows:
114 $w_1 = (1 / s_1) * (\text{total} / 2.0)$ and $w_2 = (1 / s_2) * (\text{total} / 2.0)$, where s_1 , s_2 – number of tiles for
115 subtypes 1 and 2, and total is overall number of tiles. The neural network was initialized from
116 ImageNet-pretrained ²² weights. Model training was performed for 20 epochs with 3-fold cross-
117 validation. Tiles belonging to a particular sample were included only in one subset of data – either
118 training or validation.

119 **Statistical analysis**

120 We used the area under receiver operating characteristics (ROC, AUC) curve and accuracy as
121 evaluation metrics to measure the tile-level and sample-level performance of the developed model.
122 The ROC curve was defined as false-positive rate (1-specificity) on the x-axis versus true positive
123 rate (sensitivity or recall) on the y-axis. Specificity = $TN / (TN+FP)$, Sensitivity = $TP / (TP+FN)$,
124 Accuracy = $(TP+TN) / (TP+FP+TN+FN)$, where FP, FN, TP and TN are false positives, false
125 negatives, true positives and true negatives, respectively.

126 **Nuclei segmentation**

127 Nuclei segmentation of seminoma tiles was conducted using TIA Toolbox 1.4.1²³. We applied the
128 HoVer-Net model²⁴ that has been already trained on the PanNuke dataset²⁵ and incorporated in
129 the TIA Toolbox. The calculation of nuclei size was performed using the Python library scikit-
130 image²⁶.

131 **Results and Discussion**

133 Overview of the whole experiment is shown on Figure 3. The performance of the model was
134 evaluated using the area under the ROC curve metric (Fig. 4B) and confusion matrices (Fig. 4C).
135 The developed model showed highest AUC = 0.896 (Fig. 4B). Trained model for identification of
136 pure seminoma subtypes is available in open access at GitHub
137 (<https://github.com/kirmedvedev/seminoma-subtypes>).

138 Every sample of solid tumor undergoes a detailed analysis by a professional pathologist, which
139 includes verifying the presence of cancer tissue and annotating tumor regions. This is a crucial
140 process in the clinical diagnosis routine. Inaccuracies in pathology reports can critically affect the
141 quality of patient care. An audit of pathology reports showed that if a sample size of 50 gives a
142 sample error rate of 2% there is a 95% probability that the true error rate is up to 10.9%²⁷.
143 Moreover, up to one-third of clinicians do not always understand pathology reports, leading
144 to misinterpretation and uncertainty in clinical diagnosis²⁸. DL approaches applied to
145 histopathological slide images aim to speed up the diagnosis significantly and simplify their
146 implementation into the clinical workflow. TGCTs and seminoma histopathology images, in
147 particular, have not been extensively studied using DL method, and very limited studies are
148 available nowadays. DL approaches were previously applied to TGCTs WSIs for detecting tumor-

149 infiltrating lymphocytes ²⁹, detecting lymphovascular invasion ³⁰ and developing tumor/normal
150 classifier ³¹.

151 In this report, we present our first version of the DL decision making tool for the identification of
152 pure seminoma subtypes using histopathological slides. We hypothesize that considering
153 seminoma subtypes during the development of a treatment strategy may improve its clinical
154 management, and the implementation of the developed model will enhance diagnostic accuracy
155 and reduce potential errors. This is especially crucial when subtypes cannot be distinguished by a
156 pathologist which is the case with pure seminoma. The developed model showed the capability to
157 distinguish pure seminoma subtypes (Table 1), confirming our previous findings ^{13,14}. This also
158 indicates the presence of morphological differences between seminoma subtypes. We believe that
159 the morphological differences may be due to the difference in the immune microenvironment
160 between the two subtypes. Previously, using deconvolution methods for bulk RNA-seq data of the
161 seminoma subtypes from TCGA, we showed that the neutrophil fraction is significantly higher for
162 subtype 1 ¹⁴. Moreover, according to TCGA clinical data, seminoma subtype 2 revealed an
163 increased occurrence of lymphovascular invasion, with a rate of 43% compared to 25% for subtype
164 1. We also conducted nuclei segmentation and calculated nuclei sizes for both subtypes. Our
165 analysis revealed no significant differences in nuclei size distributions between the seminoma
166 subtypes (Fig. 5A, B).

167 However, the accuracy of identifying subtype 1 samples by the developed model is higher than of
168 subtype 2 samples. This could be due to certain limitations of the model. First, the current model
169 was developed using a limited dataset. Second, only one architecture type of CNN was tested. In
170 future work, this model should be verified using an expanded dataset and several addition CNN
171 architecture types.

172 **Table 1. Prediction of seminoma subtypes using developed DL model. S1 – subtype 1, S2 –**
 173 **subtype 2.**

Sample ID	Transcriptomic subtype	DL model prediction	Sample ID	Transcriptomic subtype	DL model prediction
TCGA-XY-A9T9	S1	S1	TCGA-2G-AAH3	S1	S1
TCGA-WZ-A7V4	S1	S1	TCGA-SB-A6J6	S1	S1
TCGA-2G-AAEX	S1	S1	TCGA-2G-AAHP	S1	S1
TCGA-2G-AAF6	S1	S1	TCGA-VF-A8AB	S2	S1
TCGA-S6-A8JX	S1	S1	TCGA-ZM-AA05	S2	S2
TCGA-XY-A89B	S1	S1	TCGA-XE-AANR	S2	S2
TCGA-2G-AAFG	S1	S2	TCGA-ZM-AA0D	S2	S2
TCGA-2G-AAH8	S1	S1	TCGA-2G-AAHN	S2	S2
TCGA-2G-AAF1	S1	S1	TCGA-4K-AAAL	S2	S1
TCGA-WZ-A7V3	S1	S1	TCGA-VF-A8AE	S2	S1
TCGA-S6-A8JY	S1	S1	TCGA-ZM-AA0B	S2	S2
TCGA-VF-A8AA	S1	S1	TCGA-XE-AAOF	S2	S1
TCGA-WZ-A7V5	S1	S1	TCGA-ZM-AA0F	S2	S2
TCGA-SO-A8JP	S1	S1	TCGA-2G-AAHA	S2	S1
TCGA-XE-A8H4	S1	S1	TCGA-2G-AAHT	S2	S1
TCGA-XE-A8H5	S1	S1	TCGA-4K-AA1H	S2	S2
TCGA-XE-A9SE	S1	S2	TCGA-VF-A8A9	S2	S2
TCGA-XE-AANJ	S1	S1	TCGA-VF-A8AC	S2	S1
TCGA-XE-AANV	S1	S1	TCGA-XE-AAO6	S2	S2
TCGA-XE-AAO3	S1	S1	TCGA-XE-AAOL	S2	S2
TCGA-YU-A90Q	S1	S2	TCGA-YU-A90S	S2	S1
TCGA-YU-A90W	S1	S1	TCGA-ZM-AA06	S2	S2
TCGA-YU-A912	S1	S2	TCGA-ZM-AA0E	S2	S2
TCGA-S6-A8JW	S1	S1	TCGA-ZM-AA0H	S2	S1
TCGA-2G-AAEW	S1	S1	TCGA-ZM-AA0N	S2	S2
TCGA-2G-AAF4	S1	S1	TCGA-2G-AAHL	S2	S1
TCGA-4K-AA1I	S1	S2	TCGA-4K-AA1G	S2	S2
TCGA-2G-AAFE	S1	S1			

174

175 **Conclusion**

176 In this study we developed a DL-based model to investigate the presence of histopathological
177 distinctions between two previously identified subtypes of pure seminoma, which were initially
178 characterized using omics data. The objective was to provide further evidence supporting the
179 existence of seminoma subtypes. The results of our analysis revealed histopathological differences
180 between the two subtypes of pure seminoma. These findings provide additional confirmation and
181 support the notion that seminoma can be further stratified into distinct subtypes. These results
182 highlight the potential of histopathological analysis as a complementary tool in subtype
183 classification, offering additional insights alongside other omics-based approaches. However, our
184 study also provides evidence suggesting that pure seminoma subtypes cannot be reliably classified
185 based solely on histopathological features. Despite the observed histopathological differences
186 between the subtypes, these distinctions alone are not sufficient for accurate subtype classification.

187

188 **Funding**

189 The study is supported by the grants from the National Institute of General Medical Sciences of
190 the National Institutes of Health GM127390 (to N.V.G.), the Welch Foundation I-1505 (to
191 N.V.G.), and the National Science Foundation DBI 2224128 (to N.V.G.).

192

193 **Acknowledgements**

194 Authors are grateful to Dr. Satwik Rajaram for helpful discussions. Authors are grateful to TCGA
195 data portal for providing access to TGCT datasets. This research was supported in part by the
196 computational resources provided by the BioHPC computing facility located in the Lyda Hill
197 Department of Bioinformatics, UT Southwestern Medical Center, TX. URL:
198 <https://portal.biohpc.swmed.edu>

199

200 **Conflict of interest statement**

201 The authors declare that there are no competing interests associated with the manuscript.

202

203 **Ethics statement**

204 Not applicable.

205

206 **Figures legends**

207 **Figure 1. Slide images of samples containing additional types of GCT. (A)** TCGA-2G-AAG9.

208 **(B)** TCGA-2G-AAH0. Teratoma tissue is shown in green, embryonal carcinoma in cyan.

209

210 **Figure 2. Extraction of tiles from annotated whole slide images (WSI) of two subtypes of pure**

211 **seminoma.**

212

213 **Figure 3. Overview of dataset preparation, training and validation process.**

214

215 **Figure 4. Validation statistics. (A)** Validation accuracy. **(B)** Receiver operating characteristic

216 **(ROC)** curves for validation set. **(C)** Normalized confusion matrices.

217

218 **Figure 5. Nuclei segmentation results. (A)** Visualization of nuclei segmentation results. **(B)**

219 Comparison of seminoma cell nuclei size distribution between two subtypes.


220

221 References

- 222 1. Ghazarian AA, Trabert B, Devesa SS, McGlynn KA. Recent trends in the incidence of
223 testicular germ cell tumors in the United States. *Andrology*. Jan 2015;3(1):13-8.
224 doi:10.1111/andr.288
- 225 2. Data from: Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat
226 Database: Incidence - SEER Research Data, 8 Registries, Nov 2021 Sub (1975-2020) - Linked To
227 County Attributes - Time Dependent (1990-2020) Income/Rurality, 1969-2020 Counties, National
228 Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the
229 November 2022 submission.
- 230 3. Shin YS, Kim HJ. Current management of testicular cancer. *Korean J Urol*. Jan
231 2013;54(1):2-10. doi:10.4111/kju.2013.54.1.2
- 232 4. Chovanec M, Lauritsen J, Bandak M, et al. Late adverse effects and quality of life in
233 survivors of testicular germ cell tumour. *Nat Rev Urol*. Apr 2021;18(4):227-245.
234 doi:10.1038/s41585-021-00440-w
- 235 5. Gerl A, Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term
236 survivors of testicular cancer. *Acta Oncol*. 2000;39(4):519-22. doi:10.1080/028418600750013447
- 237 6. Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum
238 concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. *J Clin
239 Oncol*. Jan 20 2012;30(3):300-7. doi:10.1200/JCO.2011.37.4025
- 240 7. Boer H, Proost JH, Nuver J, et al. Long-term exposure to circulating platinum is associated
241 with late effects of treatment in testicular cancer survivors. *Ann Oncol*. Nov 2015;26(11):2305-10.
242 doi:10.1093/annonc/mdv369
- 243 8. Haugnes HS, Stenklev NC, Brydoy M, et al. Hearing loss before and after cisplatin-based
244 chemotherapy in testicular cancer survivors: a longitudinal study. *Acta Oncol*. Aug
245 2018;57(8):1075-1083. doi:10.1080/0284186X.2018.1433323
- 246 9. Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive Audiometric Analysis of
247 Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-
248 Onset Cancer. *J Clin Oncol*. Aug 10 2016;34(23):2712-20. doi:10.1200/JCO.2016.66.8822
- 249 10. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma
250 managed by surveillance: a pooled analysis. *J Clin Oncol*. Nov 15 2002;20(22):4448-52.
251 doi:10.1200/JCO.2002.01.038
- 252 11. Boormans JL, Mayor de Castro J, Marconi L, et al. Testicular Tumour Size and Rete Testis
253 Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients
254 Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. *Eur Urol*.
255 Mar 2018;73(3):394-405. doi:10.1016/j.eururo.2017.09.025
- 256 12. Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell
257 tumors. *Int J Urol*. Apr 2018;25(4):337-344. doi:10.1111/iju.13519
- 258 13. Medvedev KE, Savelyeva AV, Chen KS, Bagrodia A, Jia L, Grishin NV. Integrated
259 Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis. *Cancer Inform*.
260 2022;21:11769351221132634. doi:10.1177/11769351221132634
- 261 14. Savelyeva AV, Medvedev KE. Seminoma subtypes differ in the organization and
262 functional state of the immune microenvironment. *3 Biotech*. Mar 2023;13(3):110.
263 doi:10.1007/s13205-023-03530-1


- 264 15. Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in
265 cancer pathology: a new generation of clinical biomarkers. *Br J Cancer*. Feb 2021;124(4):686-
266 696. doi:10.1038/s41416-020-01122-x
- 267 16. Fritzsche FR, Ramach C, Soldini D, et al. Occupational health risks of pathologists--results
268 from a nationwide online questionnaire in Switzerland. *BMC Public Health*. Dec 6 2012;12:1054.
269 doi:10.1186/1471-2458-12-1054
- 270 17. Coudray N, Ocampo PS, Sakellaropoulos T, et al. Classification and mutation prediction
271 from non-small cell lung cancer histopathology images using deep learning. *Nat Med*. Oct
272 2018;24(10):1559-1567. doi:10.1038/s41591-018-0177-5
- 273 18. *imgaug*. 2020. Accessed accessed 01-Feb-2022. <https://github.com/aleju/imgaug>
- 274 19. Abadi M BP, Chen J, Chen Z, Davis A, Dean J, Devin M, Ghemawat S, Irving G, Isard M,
275 Kudlur M. TensorFlow: a system for Large-Scale machine learning. presented at: In 12th USENIX
276 symposium on operating systems design and implementation (OSDI 16); 2016;
- 277 20. Andrew G. Howard MZ, Bo Chen, Dmitry Kalenichenko, Weijun Wang, Tobias Weyand,
278 Marco Andreetto, Hartwig Adam. MobileNets: Efficient Convolutional Neural Networks for
279 Mobile Vision Applications. *arXiv*. 2017;doi:<https://doi.org/10.48550/arXiv.1704.04861>
- 280 21. Kingma DP BJ. Adam: A method for stochastic optimization. *arXiv*.
281 2014;doi:<https://doi.org/10.48550/arXiv.1412.6980>
- 282 22. Deng J DW, Socher R, Li LJ, Li K, Fei-Fei L. Imagenet: A large-scale hierarchical image
283 database. presented at: In 2009 IEEE conference on computer vision and pattern recognition 2009
284 Jun 20; 2009;
- 285 23. Pocock J, Graham S, Vu QD, et al. TIAToolbox as an end-to-end library for advanced
286 tissue image analytics. *Commun Med (Lond)*. 2022;2:120. doi:10.1038/s43856-022-00186-5
- 287 24. Graham S, Vu QD, Raza SEA, et al. Hover-Net: Simultaneous segmentation and
288 classification of nuclei in multi-tissue histology images. *Med Image Anal*. Dec 2019;58:101563.
289 doi:10.1016/j.media.2019.101563
- 290 25. Jevgenij Gamper NAK, Ksenija Benes, Simon Graham, Mostafa Jahanifar, Syed Ali
291 Khurram, Ayesha Azam, Katherine Hewitt, Nasir Rajpoot. PanNuke Dataset Extension, Insights
292 and Baselines. *arXiv*. 2020;doi:10.48550/arXiv.2003.10778
- 293 26. van der Walt S, Schonberger JL, Nunez-Iglesias J, et al. scikit-image: image processing in
294 Python. *PeerJ*. 2014;2:e453. doi:10.7717/peerj.453
- 295 27. Ramsay AD. Errors in histopathology reporting: detection and avoidance. *Histopathology*.
296 Jun 1999;34(6):481-90. doi:10.1046/j.1365-2559.1999.00719.x
- 297 28. Mirham L HJ, Yousef GM. Addressing the diagnostic miscommunication in pathology:
298 old challenges and innovative solutions. *American Journal of Clinical Pathology*.
299 2021;156(4):521-528. doi:<https://doi.org/10.1093/ajcp/aqab014>
- 300 29. Linder N, Taylor JC, Colling R, et al. Deep learning for detecting tumour-infiltrating
301 lymphocytes in testicular germ cell tumours. *J Clin Pathol*. Feb 2019;72(2):157-164.
302 doi:10.1136/jclinpath-2018-205328
- 303 30. Ghosh A, Sirinukunwattana K, Khalid Alham N, et al. The Potential of Artificial
304 Intelligence to Detect Lymphovascular Invasion in Testicular Cancer. *Cancers (Basel)*. Mar 16
305 2021;13(6)doi:10.3390/cancers13061325
- 306 31. Noorbakhsh J, Farahmand S, Foroughi Pour A, et al. Deep learning-based cross-
307 classifications reveal conserved spatial behaviors within tumor histological images. *Nat Commun*.
308 Dec 11 2020;11(1):6367. doi:10.1038/s41467-020-20030-5
- 309

311 **Figures**



313 Figure 1


314



315

316 Figure 2


317



318

319 Figure 3


320



321


322 Figure 4

323





324

325 Figure 5





WSI of seminoma subtype 1












20X tiles


WSI of seminoma subtype 2



20X tiles





A**B**